View Filing Data

Document and Entity Information - shares	6 Months Ended
Jun. 30, 2016	Aug. 03, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		55,600,580

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 105,701	$ 94,094
Short-term investments	7,736	7,225
Accounts receivable, net of allowance for doubtful accounts of $755 and $798	18,436	19,265
Inventories	11,366	13,242
Prepaid expenses	1,942	1,533
Other current assets	1,194	1,355
Total current assets	146,375	136,714
PROPERTY AND EQUIPMENT, net	20,200	20,083
INTANGIBLE ASSETS, net	12,020	12,591
GOODWILL	19,541	18,250
OTHER ASSETS	1,784	1,683
TOTAL ASSETS	199,920	189,321
CURRENT LIABILITIES:
Accounts payable	3,956	5,087
Deferred revenue	13,822	9,735
Accrued expenses	8,293	10,412
Total current liabilities	26,071	25,234
OTHER LIABILITIES	2,018	1,768
DEFERRED INCOME TAXES	3,043	2,883
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 55,601 and 55,705 shares issued and outstanding	0	0
Additional paid-in capital	345,093	345,253
Accumulated other comprehensive loss	(12,409)	(15,639)
Accumulated deficit	(163,896)	(170,178)
Total stockholders' equity	168,788	159,436
Total liabilities and stockholders' equity	$ 199,920	$ 189,321

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
NET REVENUES:
Product	$ 27,582	$ 26,313	$ 52,827	$ 50,078
Other	3,777	4,075	7,621	7,398
Total revenue	31,359	30,388	60,448	57,476
COST OF PRODUCTS SOLD	10,274	9,692	19,050	19,782
Gross profit	21,085	20,696	41,398	37,694
OPERATING EXPENSES:
Research and development	2,985	2,996	5,351	6,436
Sales and marketing	7,397	8,904	16,103	16,788
General and administrative	6,354	6,075	12,896	12,040
Total operating expenses	16,736	17,975	34,350	35,264
Operating income	4,349	2,721	7,048	2,430
OTHER INCOME (EXPENSE)	(340)	(95)	(532)	314
Income before income taxes	4,009	2,626	6,516	2,744
INCOME TAX EXPENSE	173	658	234	663
NET INCOME	$ 3,836	$ 1,968	$ 6,282	$ 2,081
EARNINGS PER SHARE:
BASIC	$ 0.07	$ 0.03	$ 0.11	$ 0.04
DILUTED	$ 0.07	$ 0.03	$ 0.11	$ 0.04
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	55,543	56,453	55,497	56,398
DILUTED	56,208	56,687	56,144	56,678

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
OPERATING ACTIVITIES:
NET INCOME	$ 6,282	$ 2,081
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Stock-based compensation	2,942	3,008
Depreciation and amortization	2,778	2,849
Amortization of lease incentives	(40)
Unrealized foreign currency loss	115	266
Deferred income taxes	(44)	366
Changes in assets and liabilities
Accounts receivable	893	(524)
Inventories	1,949	35
Prepaid expenses and other assets	17	(42)
Accounts payable	(782)	(2,453)
Deferred revenue	4,083	(6,256)
Accrued expenses and other liabilities	(1,452)	(2,751)
Net cash provided by (used in) operating activities	16,741	(3,421)
INVESTING ACTIVITIES:
Purchases of short-term investments	(15,335)	(11,960)
Proceeds from maturities of short-term investments	15,335	8,999
Purchases of property and equipment	(2,729)	(1,145)
Net cash used in investing activities	(2,729)	(4,106)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	209	124
Repurchase of common stock	(3,311)	(883)
Net cash used in financing activities	(3,102)	(759)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	697	(1,178)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	11,607	(9,464)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	94,094	92,867
CASH AND CASH EQUIVALENTS, END OF PERIOD	105,701	83,403
Cash paid for income taxes	556	81
Noncash investing activities (accrued property and equipment purchases)	$ 287	$ 128

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive income (loss).

Our available-for-sale securities as of June 30, 2016 and December 31, 2015 consisted of guaranteed investment certificates with amortized cost and fair value of $7,736 and $7,225, respectively.

Fair Value of Financial Instruments. As of June 30, 2016 and December 31, 2015, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Included in cash and cash equivalents at June 30, 2016 and December 31, 2015, was $84,229 and $65,509 invested in money market funds. These funds are Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of June 30, 2016 and December 31, 2015 was $1,589 and $1,324, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

All of our available-for-sale securities are measured as Level 1 instruments as of June 30, 2016 and December 31, 2015.

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	June 30, 2016		December 31, 2015
Raw materials	$	6,085	$	7,895
Work in process		497		333
Finished goods		4,784		5,014

	$	11,366	$	13,242

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Accumulated depreciation of property and equipment as of June 30, 2016 and December 31, 2015 was $34,479 and $33,013, respectively.

Intangible Assets. Intangible assets consist of the following:


			June 30, 2016
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,692	$	(4,552	)	$	5,140
Patents and product rights		10		5,400		(3,583	)		1,817
Acquired technology		7		7,528		(4,974	)		2,554
Tradename		15		3,715		(1,206	)		2,509

			$	26,335	$	(14,315	)	$	12,020


			December 31, 2015
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,051	$	(3,818	)	$	5,233
Patents and product rights		10		5,400		(3,358	)		2,042
Acquired technology		7		7,030		(4,172	)		2,858
Tradename		15		3,469		(1,011	)		2,458

			$	24,950	$	(12,359	)	$	12,591

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values.

We performed our last annual impairment assessment as of July 31, 2015 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of June 30, 2016, we believe no indicators of impairment exist.

The change in goodwill from $18,250 as of December 31, 2015 to $19,541 as of June 30, 2016 is a result of foreign currency translation.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick^® In-Home HIV test to the retail trade, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances for cooperative advertising, discounts, rebates, and chargebacks are contractual in nature. These allowances are recorded as a reduction of gross revenue when recognized in our consolidated statements of income.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick^® HCV test in the United States.

Pursuant to the agreement, we granted exclusive co-promotion rights for the OraQuick^® HCV test in certain markets to AbbVie and we agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database is being used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick^® HCV test. We also jointly agreed with AbbVie to co-promote our OraQuick^® HCV test in certain market segments.

Under the terms of this agreement, we are eligible to receive up to $75,000 in aggregate payments. We are recognizing this revenue ratably on a monthly basis over the term of the agreement which was to terminate on December 31, 2019. During the second quarter and first six months of 2016, $3,360 and $6,722, respectively, in exclusivity revenue was recognized and was recorded as other revenue in our consolidated statements of income.

Effective June 30, 2016, we mutually agreed to an early termination of this agreement with AbbVie and it will now end on December 31, 2016. Following the termination of the agreement, AbbVie will be relieved of its co-promotion obligations, including its obligation to detail the OraQuick^® HCV Rapid Test into physician offices, and will have no further financial obligations to us. We will no longer be obligated to compensate AbbVie for product detailing activities and will be free to pursue arrangements with other pharmaceutical companies to market and promote our OraQuick^® HCV Rapid Antibody Test in the U.S. As a result of the shortened term, the remaining associated deferred revenue of $12.2 million at June 30, 2016, will be recognized ratably as other revenue over the remaining six months of 2016 as there are no substantive on-going obligations remaining beyond December 31, 2016.

On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to the development of our OraQuick^® Ebola Rapid Antigen test. The three-year, multi-phased grant includes an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015, BARDA exercised an option to provide $7,200 in additional funding for the development of our OraQuick^® Ebola Rapid Antigen test. Amounts related to this grant are recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the second quarter and first six months of 2016, $417 and $899, respectively, was recognized in connection with this grant.

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of June 30, 2016 and December 31, 2015, the reserve for sales returns and allowances was $328 and $310, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2016 and December 31, 2015 includes customer prepayments of $1,593 and $784, respectively. Deferred revenue as of June 30, 2016 and December 31, 2015 also includes $12,229 and $8,951, respectively, from AbbVie, which represents the excess of the payments received from AbbVie over the amounts earned and recognized ratably in our consolidated statements of income.

Customer and Vendor Concentrations. One of our customers accounted for approximately 13% of our accounts receivable as of June 30, 2016. We had no significant concentrations in accounts receivable as of December 31, 2015. Another customer accounted for approximately 11% of our net revenues for the three and six months ended June 30, 2016, respectively. The same customer accounted for approximately 11% and 12% of our net revenues for the three and six months ended June 30, 2015, respectively.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:


	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2016		2015		2016		2015
Net income	$	3,836	$	1,968	$	6,282	$	2,081

Weighted average shares of common stock outstanding:
Basic		55,543		56,453		55,497		56,398
Dilutive effect of stock options and restricted stock		665		234		647		280

Diluted		56,208		56,687		56,144		56,678

Earnings per share:
Basic	$	0.07	$	0.03	$	0.11	$	0.04

Diluted	$	0.07	$	0.03	$	0.11	$	0.04

For the three-month periods ended June 30, 2016 and 2015, outstanding common stock options and unvested restricted stock representing 2,459 and 5,010 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the six months ended June 30, 2016 and 2015, outstanding common stock options and unvested restricted stock representing 3,191 and 3,856 shares, respectively, were similarly excluded from the computation of diluted earnings per share.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(302) and $(47) for the three months ended June 30, 2016 and 2015, respectively. Net foreign exchange gains (losses) were $(648) and $541 for the six months ended June 30, 2016 and 2015, respectively.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive income (loss) separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $3,230 and $(3,178) currency translation adjustments recorded in the first six months of 2016 and 2015, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.

Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, with early adoption permitted. We are still evaluating the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires an entity that uses the first-in, first-out method for inventory measurement to report inventory cost at the lower of cost and net realizable value versus the current measurement principle of lower of cost or market. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016. Early adoption is permitted. We are evaluating the effect that ASU 2015-11 may have on our consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures.

In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 provides for simplification of several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The Company is required to adopt this new authoritative guidance in the first quarter of fiscal 2018. Early adoption is permitted. The Company is currently evaluating the potential impact of adoption of this standard on its consolidated financial statements.

Business Segment Information

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Business Segment Information

7.	Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including exclusivity payments for co-promotion rights and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, animal and livestock genetic testing, and microbiome testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three and six months ended June 30, 2016 and 2015, and asset information as of June 30, 2016 and December 31, 2015:


	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Net revenues:
OSUR	$	22,926	$	22,286	$	45,125	$	42,657
DNAG		8,433		8,102		15,323		14,819

Total	$	31,359	$	30,388	$	60,448	$	57,476

Operating income (loss):
OSUR	$	2,919	$	685	$	4,526	$	(836	)
DNAG		1,430		2,036		2,522		3,266

Total	$	4,349	$	2,721	$	7,048	$	2,430

Depreciation and amortization:
OSUR	$	661	$	734	$	1,315	$	1,460
DNAG		747		706		1,463		1,389

Total	$	1,408	$	1,440	$	2,778	$	2,849

Capital expenditures:
OSUR	$	661	$	490	$	1,123	$	566
DNAG		460		218		1,606		579

Total	$	1,121	$	708	$	2,729	$	1,145


	June 30, 2016		December 31, 2015
Total assets:
OSUR	$	143,772	$	137,082
DNAG		56,148		52,239

Total	$	199,920	$	189,321

Our products are sold principally in the United States and Europe.

The following table represents total revenues by geographic area, based on the location of the customer:


	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
United States	$	24,021	$	25,071	$	46,191	$	45,488
Europe		2,957		2,939		6,836		7,313
Other regions		4,381		2,378		7,421		4,675

	$	31,359	$	30,388	$	60,448	$	57,476

The following table represents total long-lived assets by geographic area:


	June 30, 2016		December 31, 2015
United States	$	15,665	$	15,660
Canada		4,511		4,415
Other regions		24		8

	$	20,200	$	20,083

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Short-Term Investments

Our available-for-sale securities as of June 30, 2016 and December 31, 2015 consisted of guaranteed investment certificates with amortized cost and fair value of $7,736 and $7,225, respectively.

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Included in cash and cash equivalents at June 30, 2016 and December 31, 2015, was $84,229 and $65,509 invested in money market funds. These funds are Level 1 instruments.

All of our available-for-sale securities are measured as Level 1 instruments as of June 30, 2016 and December 31, 2015.

Inventories

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	June 30, 2016		December 31, 2015
Raw materials	$	6,085	$	7,895
Work in process		497		333
Finished goods		4,784		5,014

	$	11,366	$	13,242

Property and Equipment

Intangible Assets

Intangible Assets. Intangible assets consist of the following:


			June 30, 2016
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,692	$	(4,552	)	$	5,140
Patents and product rights		10		5,400		(3,583	)		1,817
Acquired technology		7		7,528		(4,974	)		2,554
Tradename		15		3,715		(1,206	)		2,509

			$	26,335	$	(14,315	)	$	12,020


			December 31, 2015
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,051	$	(3,818	)	$	5,233
Patents and product rights		10		5,400		(3,358	)		2,042
Acquired technology		7		7,030		(4,172	)		2,858
Tradename		15		3,469		(1,011	)		2,458

			$	24,950	$	(12,359	)	$	12,591

Goodwill

The change in goodwill from $18,250 as of December 31, 2015 to $19,541 as of June 30, 2016 is a result of foreign currency translation.

Revenue Recognition

Customer Sales Returns and Allowances

Deferred Revenue

Customer and Vendor Concentrations

Earnings Per Share

The computations of basic and diluted earnings per share are as follows:


	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2016		2015		2016		2015
Net income	$	3,836	$	1,968	$	6,282	$	2,081

Weighted average shares of common stock outstanding:
Basic		55,543		56,453		55,497		56,398
Dilutive effect of stock options and restricted stock		665		234		647		280

Diluted		56,208		56,687		56,144		56,678

Earnings per share:
Basic	$	0.07	$	0.03	$	0.11	$	0.04

Diluted	$	0.07	$	0.03	$	0.11	$	0.04

Foreign Currency Translation

Accumulated Other Comprehensive Loss

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	June 30, 2016		December 31, 2015
Raw materials	$	6,085	$	7,895
Work in process		497		333
Finished goods		4,784		5,014

	$	11,366	$	13,242

Summary of Intangible Assets

Intangible assets consist of the following:


			June 30, 2016
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,692	$	(4,552	)	$	5,140
Patents and product rights		10		5,400		(3,583	)		1,817
Acquired technology		7		7,528		(4,974	)		2,554
Tradename		15		3,715		(1,206	)		2,509

			$	26,335	$	(14,315	)	$	12,020


			December 31, 2015
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,051	$	(3,818	)	$	5,233
Patents and product rights		10		5,400		(3,358	)		2,042
Acquired technology		7		7,030		(4,172	)		2,858
Tradename		15		3,469		(1,011	)		2,458

			$	24,950	$	(12,359	)	$	12,591

Computations of Basic and Diluted Earnings per Share

The computations of basic and diluted earnings per share are as follows:


	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2016		2015		2016		2015
Net income	$	3,836	$	1,968	$	6,282	$	2,081

Weighted average shares of common stock outstanding:
Basic		55,543		56,453		55,497		56,398
Dilutive effect of stock options and restricted stock		665		234		647		280

Diluted		56,208		56,687		56,144		56,678

Earnings per share:
Basic	$	0.07	$	0.03	$	0.11	$	0.04

Diluted	$	0.07	$	0.03	$	0.11	$	0.04

Business Segment Information (Tables)

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and six months ended June 30, 2016 and 2015, and asset information as of June 30, 2016 and December 31, 2015:


	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Net revenues:
OSUR	$	22,926	$	22,286	$	45,125	$	42,657
DNAG		8,433		8,102		15,323		14,819

Total	$	31,359	$	30,388	$	60,448	$	57,476

Operating income (loss):
OSUR	$	2,919	$	685	$	4,526	$	(836	)
DNAG		1,430		2,036		2,522		3,266

Total	$	4,349	$	2,721	$	7,048	$	2,430

Depreciation and amortization:
OSUR	$	661	$	734	$	1,315	$	1,460
DNAG		747		706		1,463		1,389

Total	$	1,408	$	1,440	$	2,778	$	2,849

Capital expenditures:
OSUR	$	661	$	490	$	1,123	$	566
DNAG		460		218		1,606		579

Total	$	1,121	$	708	$	2,729	$	1,145


	June 30, 2016		December 31, 2015
Total assets:
OSUR	$	143,772	$	137,082
DNAG		56,148		52,239

Total	$	199,920	$	189,321

Presentation of Total Revenues and Long-Lived Assets by Geographic Area

The following table represents total revenues by geographic area, based on the location of the customer:


	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
United States	$	24,021	$	25,071	$	46,191	$	45,488
Europe		2,957		2,939		6,836		7,313
Other regions		4,381		2,378		7,421		4,675

	$	31,359	$	30,388	$	60,448	$	57,476

The following table represents total long-lived assets by geographic area:


	June 30, 2016		December 31, 2015
United States	$	15,665	$	15,660
Canada		4,511		4,415
Other regions		24		8

	$	20,200	$	20,083

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 12, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) Supplier shares	Jun. 30, 2015 USD ($) shares	Jun. 30, 2016 USD ($) Supplier shares	Jun. 30, 2015 USD ($) shares	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, fair values			$ 7,736,000		$ 7,736,000		$ 7,225,000
Cash and cash equivalents			105,701,000	$ 83,403,000	105,701,000	$ 83,403,000	94,094,000	$ 92,867,000
Fair value of plan assets			1,589,000		1,589,000		1,324,000
Accumulated depreciation of property and equipment			34,479		34,479		33,013
Amount of goodwill at period end			19,541,000		$ 19,541,000		18,250,000
Expiration date of rights agreement					Dec. 31, 2019
Revenue recognized			3,360,000		$ 6,722,000
Deferred revenue			13,822,000		13,822,000		9,735,000
Maximum value of grant revenue from clinical and regulatory activities	$ 10,400,000
Initial grant revenue from clinical and regulatory activities	1,800,000
Remaining grant revenue from clinical and regulatory activities	$ 8,600,000
Period of grant	3 years
Additional contract revenue from clinical and regulatory activities		$ 7,200,000
Reserve for sales return and allowances					328,000		310,000
Net foreign exchange gains (losses)			(302,000)	(47,000)	(648,000)	541,000
Accumulated foreign currency adjustments included in other comprehensive loss amounted			3,230,000	$ (3,178,000)	3,230,000	$ (3,178,000)
Money Market Fund [Member] \| Level I Instrument [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents			$ 84,229,000		$ 84,229,000		$ 65,509,000
Common Stock Options and Unvested Restricted Stock [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation \| shares			2,459	5,010	2,459	5,010
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk							0.00%
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue			$ 1,593,000		$ 1,593,000		$ 784,000
AbbVie [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue			12,229,000		$ 12,229,000		8,951,000
AbbVie [Member] \| Collaborative Arrangement Co-promotion [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expiration date of rights agreement					Dec. 31, 2016
Deferred revenue			$ 12,200,000		$ 12,200,000
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk					13.00%
Customer Two [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk			11.00%	11.00%	11.00%	12.00%
Guaranteed Investment Certificates [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, amortized cost			$ 7,736,000		$ 7,736,000		7,736,000
Available-for-sale securities, fair values			7,225,000		7,225,000		$ 7,225,000
Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract revenues from clinical and regulatory activities			$ 417,000		899,000
Maximum [Member] \| Collaborative Arrangement Co-promotion [Member] \| OraQuick HCV [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Payments received for sale of exclusive rights					$ 75,000,000
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					10 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					2 years
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier			2		2

Stockholders' Equity - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	$ 209,000	$ 124,000
Income tax benefit realized from stock option exercises during period	0	0
Total compensation cost	$ 2,942,000	$ 3,008,000
Amount share repurchase program of common shares			$ 25,000,000
Stock Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	423	0
Average price of common stock	$ 6.29
Total cost of common stock purchased and retired	$ 2,660,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	209,000	$ 124,000
Total compensation cost	1,387,000	1,690,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,401,000	$ 1,318,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations	117,000	132,000
Restricted shares of common stock and stock options, aggregate values	$ 651,000	$ 883,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
PSU Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
PSU Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 154,000

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 755	$ 798
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	55,601,000	55,705,000
Common stock, shares outstanding	55,601,000	55,705,000

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 26,335	$ 24,950
Intangible Assets, Accumulated Amortization	(14,315)	(12,359)
Intangible Assets, Net	$ 12,020	$ 12,591
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 9,692	$ 9,051
Intangible Assets, Accumulated Amortization	(4,552)	(3,818)
Intangible Assets, Net	$ 5,140	$ 5,233
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 5,400	$ 5,400
Intangible Assets, Accumulated Amortization	(3,583)	(3,358)
Intangible Assets, Net	$ 1,817	$ 2,042
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Intangible Assets, Gross	$ 7,528	$ 7,030
Intangible Assets, Accumulated Amortization	(4,974)	(4,172)
Intangible Assets, Net	$ 2,554	$ 2,858
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years
Intangible Assets, Gross	$ 3,715	$ 3,469
Intangible Assets, Accumulated Amortization	(1,206)	(1,011)
Intangible Assets, Net	$ 2,509	$ 2,458

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 4,172	$ 6,311
Professional fees	1,177	1,014
Royalties	830	819
Other	2,114	2,268
Accrued Expenses, Total	$ 8,293	$ 10,412

Income Taxes - Components of Income Tax Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Current taxes	$ 199	$ 292	$ 278	$ 297
Deferred taxes	(26)	366	(44)	366
Total	$ 173	$ 658	$ 234	$ 663

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory, Net [Abstract]
Raw materials	$ 6,085	$ 7,895
Work in process	497	333
Finished goods	4,784	5,014
Inventories	$ 11,366	$ 13,242